RxDoctor Payments Data

Keith Stokes, MD

Family Medicine · Lexington, MSNPI 1821297961

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $652,000 of the $653,793 with a category attached, or 99.7%. 8 manufacturers reported payments, led by CSL Plasma Inc. at 54.0% of the total. Among family medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$653,793in general payments, 2019–2025

Across 417 payments — averaging $1567.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Plasma Inc.$353K
  • CSL Behring$299K
  • Gilead$797
  • Merck$397
  • Viiv Healthcare Company$260
  • Janssen Products, LP$199
  • plus $139 from 2 others
$6,015in research payments, 2019–2025

Across 2 payments — averaging $3007.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • BD$6K

What the payments were for

  • Consulting fees$652,000100%
  • Food & beverage$1,5940%
  • Education$1990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
CSL Plasma Inc.176$353,000
CSL Behring162$299,000
Gilead37$797
Merck15$397
Viiv Healthcare Company15$260
Janssen Products, LP2$199
Johnson & Johnson(2 entities)7$102
Theratechnologies Inc.3$37

How this compares

$653,793 in reported general payments places this provider in the 95th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$2,851
Medicare patients
16
Services billed
34

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala32$137,514
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$44,908
EliquisApixaban12$9,671
Levothyroxine Sodium24$140
Methimazole13$118
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$82
Isosorbide Mononitrate ErIsosorbide Mononitrate11$61
Pravastatin Sodium11$59
Atorvastatin Calcium17$55
Lisinopril13$27
Amlodipine Besylate20$22

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$797$182,42244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Lexington

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →